Iconovo AB announced that it has signed an agreement with Intas Pharmaceuticals for development and licensing of a DPI for the treatment of asthma and COPD, including the dry powder formulation and a device based on Iconovo’s ICOres reservoir inhaler. According to Iconovo, the deal is worth €2.8 million and includes royalties.
In June 2017, Iconovo announced the addition of drug formulation services and a development and licensing agreement with Amneal Pharmaceuticals for a DPI, also based on the ICOres inhaler.
Iconovo CEO Orest Lastow commented, “This second agreement is an important milestone for Iconovo. Once again, we validate our business model and capabilities as well as a recognition of our inhalers and our formulation development. We are thrilled to partner with Intas Pharmaceuticals in this development project.”
Intas said that it “is delighted to strike this deal with Iconovo and entering, this way, in the challenging respiratory field with this first development and licensing agreement.”
Read the Iconovo press release.
